Digital program to reduce depression and cannabis use
Official title: AMP-C: A Digital Therapeutic for Reward Dysfunction in Co-Occurring Depression and Cannabis Use
Run by Massachusetts General Hospital · NCT06878859 · Data updated 2026-11-12
This trial will test a digital program called AMP-C to see if it reduces depressive symptoms and cannabis use in adults with both major depression and problematic cannabis use.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | Massachusetts General Hospital Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Status | Recruiting |
| Started | February 23, 2026 |
| Main results expected | January 31, 2028 |
| Study ends | June 29, 2029 |
| Registry record updated | June 2, 2026 |
| Trial ID | NCT06878859 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) living in the U.S. who read English, meet DSM-5 criteria for current major depressive disorder and cannabis use disorder, have moderate depressive symptoms and problematic cannabis use with elevated anhedonia, and are interested in treatment are ideal candidates.
✕Probably not a fit
People with a history of psychotic or bipolar disorder, active suicidal ideation, current psychotherapy engagement, recent psychotropic medication changes, non-English speakers, or those living outside the U.S. may not benefit from or be eligible for this program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults with co-occurring major depressive disorder and cannabis use disorder are randomized to the Amplification of Positivity - Cannabis Use (AMP-C) digital intervention or to symptom tracking. The trial measures changes in depressive symptoms and cannabis use, along with usability and acceptability ratings, over a short follow-up period. Key inclusion criteria require moderate depressive symptoms, problematic cannabis use, elevated anhedonia, and interest in treatment, while exclusion criteria rule out psychotic or bipolar disorders, active suicidal intent, current psychotherapy, or recent medication changes. The intervention is delivered digitally through Massachusetts General Hospital and aims to gather feasibility and preliminary efficacy data before larger-scale testing.
Why it matters
Potential benefit: If successful, the program could provide an accessible digital option to reduce depressive symptoms and cannabis use for people with both conditions.
How similar studies have gone: Digital treatments have shown promise for depression and for substance use separately, but interventions specifically targeting co-occurring cannabis use and depression are relatively novel with limited prior data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged ≥ 18 years * Resides in the United States * Able to read and understand English and willing to provide informed consent/comply with the study protocol * Moderate depressive symptom severity, as indicated by the Patient Health Questionnaire-9 (PHQ-9) * Problematic cannabis use, as indicated by the Cannabis Use Disorder Identification Test - Revised (CUDIT-R) * Current elevated anhedonia, as indicated by the PHQ-9 * Interest in receiving treatment for their cannabis use and depression * Meet criteria for current MDD and CUD per the DSM-5 Exclusion Criteria: * History of a psychotic disorder or bipolar disorder type I/II * Active suicidal ideation or intent based on the Columbia-Suicide Severity Rating Scale * Current psychotherapy engagement * Changes in psychotropic medication within six weeks of the start of study
Where it's running
-
Massachusetts General Hospital
Boston, Massachusetts, United States Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Can tACS modulate motivation and reward signals in cannabis use disorder and depression
We’re testing whether a gentle brain stimulation method (tACS) can boost motivation and reward responses in adults with cannabis use and/or depression to see if it helps with anhedonia.
-
Understanding how the orbitofrontal cortex guides approach vs. avoidance in depression
This study tests how different parts of the orbitofrontal cortex influence whether people pursue rewards or risk loss, and whether this pattern is altered in Major Depressive Disorder.
-
Health education program to help depression in older adults and caregivers in Ho Chi Minh City
A community-based education program for people 60+ and their caregivers is being tested to see if it can lower depression and improve quality of life compared with standard care.
-
Prucalopride for low mood: testing a 5-HT4 receptor activator for cognition and sleep
This study tests whether prucalopride, a 5-HT4 receptor drug, can improve thinking and sleep in adults with low mood or major depressive disorder compared to a placebo.
-
Pre-visit Companion Brief: a primary care AI-assisted check for depression and anxiety
This pilot tests an AI-powered pre-visit assessment that creates a concise Companion Brief for clinicians to help identify depression and anxiety during routine primary care.
-
Sex differences in how cannabis affects people who regularly use it
This Phase 2 trial tests whether men and women who use cannabis several days a week respond differently to THC versus placebo.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.